

Appl. No. : 10/644,277
Filed : August 19, 2003

AMENDMENTS TO THE CLAIMS

1. (Currently amended) A human monoclonal antibody that binds to MCP-1 and comprises a heavy chain amino-acid polypeptide having a the sequence selected from the group consisting of SEQ ID NOS: NO.: 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42, 46, 50, 54, 58, 62, 66, 70, 74, 78, 82, 86, 90, 94, 98, 102, 106, 110, 114, 118, 122, 126, 130, 134, 138, 142 and 146.

2. (Currently amended) The antibody of Claim 1, further comprising a light chain amino-acid polypeptide having a the sequence selected from the group consisting of SEQ ID NOS: NO.: 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, 112, 116, 120, 124, 128, 132, 136, 140, 144 and 148.

3-40 (Cancelled)

41. (Currently amended) An antibody immobilized on an insoluble matrix, wherein the antibody is the antibody of Claim 2-1.

42. (Withdrawn amended) An improved A method for assaying the level of monocyte chemo-attractant protein (MCP-1) in a patient sample, wherein said improved method comprises comprising:

the use of contacting the anti-MCP-1 antibody of Claim 2-1 with the patient sample, and
for detection of detecting the level of MCP-1 in the assay of a patient sample.

43. (Withdrawn) A method according to Claim 42 wherein the patient sample is blood.

44. (Currently amended) A composition, comprising the antibody or fragment thereof of Claim 2-1, and a pharmaceutically acceptable carrier.

45. (Withdrawn amended) A method of effectively treating a neoplastic disease, comprising:

selecting an animal in need of treatment for a neoplastic disease;
administering to said animal a therapeutically effective dose of the antibody or fragment thereof of Claim 1.

46. (Withdrawn) The method of claim 45, wherein said neoplastic disease is selected from the group consisting of: breast cancer, ovarian cancer, bladder cancer, lung cancer,

glioblastoma, stomach cancer, endometrial cancer, kidney cancer, colon cancer, pancreatic cancer, and prostate cancer.

47. **(Withdrawn amended)** A method of effectively treating inflammatory conditions, comprising:

selecting an animal in need of treatment for an inflammatory condition;
administering to said animal a therapeutically effective dose of the antibody ~~or fragment thereof~~ of Claim 1.

48. **(Withdrawn)** The method of claim 47, wherein said inflammatory condition is selected from the group consisting of: rheumatoid arthritis, glomerulonephritis, atherosclerosis, psoriasis, restenosis, autoimmune disease, and multiple sclerosis.

49. **(Previously presented)** The human monoclonal antibody of Claim 2, wherein the monoclonal antibody is monoclonal antibody 3.11.1 or 3.11.2.

50. **(Previously presented)** A human monoclonal antibody that cross-competes for binding to MCP-1 with fully human monoclonal antibody 3.11.1 or 3.11.2.

51. **(Currently amended)** A human monoclonal antibody that binds to the sequence ISVQRLASYRRITSSK (SEQ ID NO.: 150).

52. **(Previously presented)** The antibody of Claim 51, wherein the antibody is monoclonal antibody 3.11.1 or 3.11.2.

53. **(New)** A method of manufacturing the antibody of Claim 1, comprising:
immunizing a mammal with a synthetic peptide of MCP-1;
recovering a lymphatic cell that expresses the antibody of Claim 1 from the immunized mammal; and
fusing the lymphatic cell with a myeloid-type cell to prepare a hybridoma cell that produces the antibody of Claim 1.